An Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as 6-Day Continuous Infusions to Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2009
At a glance
- Drugs Danegaptide (Primary)
- Indications Arrhythmias
- Focus Adverse reactions
- Sponsors Wyeth
- 22 Jul 2009 Actual patient number (25) added as reported by ClinicalTrials.gov.
- 22 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Feb 2009 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.